ME Stock Recent News
ME LATEST HEADLINES
The at-home genetic testing company is dealing with financial woes and a security breach. What does that mean for customers?
23andMe reported dismal third-quarter fiscal 2024 results and discussed splitting itself in two to help juice its stock price.
Shares of 23andMe Holding Co. fell 15.8% Thursday after the DNA-testing company fiscal third-quarter sales declined 33%, weighed down by lower consumer services and research revenue.
23andMe Holding Co. (ME) Q3 2024 Earnings Call Transcript
23andMe stock is down over 95% from its peak, cutting its value from $6 billion to $345 million. The genetic-testing company is facing financial and strategic challenges, and was hacked last year.
23andMe Holding Co.'s (NASDAQ: ME) plans have come under attack by investors and the media after 23andMe stock collapsed in the past year.
The class-action suit said the genetic testing company failed to notify customers whose personal information was compiled into “curated” lists that were sold on the dark web.
In a data breach notification letter filed with regulators this weekend, 23andMe revealed that hackers started breaking into customers' accounts in April 2023 and continued through most of September.
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fiscal year 2024 (FY2024) third quarter after the market closes on Wednesday, February 7, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's financial results and report on business progress.
Home DNA testing firm 23andMe is placing the blame on customers who reused login credentials for a cyber incident in which 6.9 million customers' data was exposed.